Show simple item record

dc.contributor.advisorWilson, Jean M.en
dc.contributor.authorRygelski, Marian Mikaela
dc.creatorRygelski, Marian Mikaelaen
dc.date.accessioned2018-01-23T23:34:21Z
dc.date.available2018-01-23T23:34:21Z
dc.date.issued2017
dc.identifier.urihttp://hdl.handle.net/10150/626402
dc.description.abstractHuman Immunodeficiency Virus Type I, or HIV, is one of the most well-known and well-researched viruses in the world. The current standard of care for HIV infected individuals is an antiretroviral drug therapy regiment, or ART, started immediately after diagnosis. While this treatment is generally quite effective at keeping the viral load low and stopping the progression from HIV infection to AIDS, patients receiving ART therapy still have a lower life expectancy than uninfected individuals. Many times, the cause of death in these patients is not the common opportunistic pathogens and cancers linked to HIV and AIDS, but chronic health conditions that develop. One of these conditions that is seen in many of the HIV infected patients undergoing the antiretroviral therapy is cardiovascular disease, such as atherosclerosis and myocardial infarction. Research shows that one of the key players in developing these conditions in HIV patients is the chronic inflammation caused by the immune system attempts to control the level of the virus. By studying the links between HIV, inflammation, and cardiovascular disease, we may be able to find solutions to the development of chronic disease in HIV patients on antiretroviral therapy.
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.en
dc.subjectAtherosclerosisen
dc.subjectCardiovascular Diseaseen
dc.subjectHIVen
dc.subjectHuman Immunodeficiency Virusen
dc.subjectInflammationen
dc.subjectPathogenesisen
dc.titleThe Role of Inflammation in Cardiovascular Disease in HIV-Infected Patientsen_US
dc.typetexten
dc.typeElectronic Thesisen
thesis.degree.grantorUniversity of Arizonaen
thesis.degree.levelmastersen
dc.contributor.committeememberWilson, Jean M.en
dc.contributor.committeememberConnick, Elizabethen
dc.contributor.committeememberRunyan, Raymond B.en
thesis.degree.disciplineGraduate Collegeen
thesis.degree.disciplineCellular and Molecular Medicineen
thesis.degree.nameM.S.en
refterms.dateFOA2018-08-13T23:50:53Z
html.description.abstractHuman Immunodeficiency Virus Type I, or HIV, is one of the most well-known and well-researched viruses in the world. The current standard of care for HIV infected individuals is an antiretroviral drug therapy regiment, or ART, started immediately after diagnosis. While this treatment is generally quite effective at keeping the viral load low and stopping the progression from HIV infection to AIDS, patients receiving ART therapy still have a lower life expectancy than uninfected individuals. Many times, the cause of death in these patients is not the common opportunistic pathogens and cancers linked to HIV and AIDS, but chronic health conditions that develop. One of these conditions that is seen in many of the HIV infected patients undergoing the antiretroviral therapy is cardiovascular disease, such as atherosclerosis and myocardial infarction. Research shows that one of the key players in developing these conditions in HIV patients is the chronic inflammation caused by the immune system attempts to control the level of the virus. By studying the links between HIV, inflammation, and cardiovascular disease, we may be able to find solutions to the development of chronic disease in HIV patients on antiretroviral therapy.


Files in this item

Thumbnail
Name:
azu_etd_15980_sip1_m.pdf
Size:
11.82Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record